Medasense's PMD-200 is an FDA-cleared, CE-marked AI-powered pain monitoring device that uses the Nociception Level Index (NOL) technology to objectively assess nociception in anesthetized patients.
The intelligence layer is actively learning. HAS scores are continuously refined as new signals and intelligence enter the platform.The intelligence layer is actively learning.
Medasense's PMD-200 is an FDA-cleared, CE-marked AI-powered pain monitoring device that uses the Nociception Level Index (NOL) technology to objectively assess nociception in anesthetized patients.